Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586579 | 0.85 | RAB9A (0.50) | POLBPTGESMAPTRAB9ANPSR1 | |
| SCHEMBL3578915 | 0.83 | MEN1 (0.48) | MAPTRAB9ANPSR1CYP19A1CYP11B1 | |
| SCHEMBL25431681 | 0.83 | NPC1 (0.54) | MAPTRAB9ANPSR1CYP19A1CYP11B1 | |
| SCHEMBL1936411 | 0.82 | CYP11B1 (0.54) | POLBMAPTRAB9ANPSR1CYP19A1 | |
| SCHEMBL6904365 | 0.81 | POLB (0.56) | POLBPTGESMAPTRAB9AMAOB | |
| SCHEMBL20189613 | 0.81 | CYP17A1 (0.41) | POLBMAPTRAB9A | |
| SCHEMBL3590484 | 0.79 | HTT (0.46) | MAPTRAB9ANPSR1CYP19A1CYP11B1 | |
| SCHEMBL3585058 | 0.79 | MGMT (0.52) | MAPTRAB9ANPSR1CYP19A1CYP11B1 | |
| SCHEMBL2771800 | 0.75 | MAPT (0.48) | PTGESMAPTRAB9ANPSR1CYP19A1 | |
| SCHEMBL4721194 | 0.74 | MEN1 (0.51) | POLBMAPTRAB9AATG4BTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784403-B1 | PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2013-07-17 | — | — | EP | disclosed |
| US-7642269-B2 | Pyrrolo[3,2-B]pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2010-01-05 | — | — | US | disclosed |
| US-20070213358-A1 | PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2007-09-13 | — | — | US | disclosed |
| EP-1784403-A1 | PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2007-05-16 | — | — | EP | disclosed |
| WO-2007001139-A1 | A COMPOSITION FOR TREATING OR PREVENTING A CANCER COMPRISING PYRROLOPYRIDINE DERIVATIVES | YUHAN CORPORATION (KR) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006038773-A1 | PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213358-A1 | PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | PGA5, ATP6AP1, PPOX | POLB 1720/4885PTGES 530/4885MAPT 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.